These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 6210188

  • 21. [Clinical evaluation of CA 19-9 for the detection of malignant tumors--a comparison with CEA and IAP].
    Furukawa M, Kazaka S, Kushibiki K, Ashida Y, Saito H, Yamamoto H, Furukawa T.
    Gan No Rinsho; 1984 Apr; 30(4):357-62. PubMed ID: 6587133
    [Abstract] [Full Text] [Related]

  • 22. Carbohydrate antigen (CA 19-9)--a valuable tumor marker of pancreatic cancer.
    Lin JT, Wang TH, Sung JL, Chen DS.
    Taiwan Yi Xue Hui Za Zhi; 1985 Jul; 84(7):828-35. PubMed ID: 3864924
    [No Abstract] [Full Text] [Related]

  • 23. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
    Röthlin M, Metzger U, Joller H, Largiadèr F.
    Schweiz Med Wochenschr; 1988 Jun 18; 118(24):924-9. PubMed ID: 2456610
    [Abstract] [Full Text] [Related]

  • 24. [Attention to CA 19.9 in alcoholics. Apropos of a case].
    Giovannini M, Penalvert F, Maillot A, Escoffier JM, Botta D, Gauthier A.
    Ann Gastroenterol Hepatol (Paris); 1987 Dec 18; 23(7):393. PubMed ID: 3481241
    [No Abstract] [Full Text] [Related]

  • 25. [Monoclonal antibodies in the radioimmunological diagnosis of malignant tumors of the gastrointestinal tract and ovaries].
    Tkacheva GA, Blokhina NG, Klimenkov AA, Kozachenko VP.
    Vopr Onkol; 1985 Dec 18; 31(5):36-42. PubMed ID: 2409674
    [Abstract] [Full Text] [Related]

  • 26. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.
    Harmenberg U, Wahren B, Wiechel KL.
    Cancer Res; 1988 Apr 01; 48(7):1985-8. PubMed ID: 3349472
    [Abstract] [Full Text] [Related]

  • 27. Clinical experience with the tumor marker Ca 19-9 in an unselected group of more than 300 tumor patients.
    Souchon R, Koppenhagen K, Souchon MF, Matthes M, Boese-Landgraf J, Fitzner R, Baer U.
    Cancer Detect Prev; 1985 Apr 01; 8(1-2):101-9. PubMed ID: 3864534
    [Abstract] [Full Text] [Related]

  • 28. [Significance of a new tumor marker (CA 19-9) in the differential diagnosis of pathological changes in the pancreas detected by ultrasonic diagnosis].
    Bohár L, Szilvási I, Bodorné N, Varsányi N, Barda L, Sarkadi G.
    Orv Hetil; 1985 Oct 13; 126(41):2525-7. PubMed ID: 3900874
    [No Abstract] [Full Text] [Related]

  • 29. [Pancreatic oncofetal antigen (POA)].
    Mugitani H, Furue H, Kako M, Hirota F, Fuse K, Takahashi T, Sakamoto K, Yamada K, Suminaga M, Ezaki M, Judo R.
    Gan To Kagaku Ryoho; 1983 Aug 13; 10(8):1737-43. PubMed ID: 6882002
    [Abstract] [Full Text] [Related]

  • 30. [Evaluation of a monoclonal antibody (CA 19-9 system) in gastrointestinal disease--in comparison with CEA and IAP].
    Furukawa M, Kozaka S, Kushibiki K, Ashida Y, Saito H, Yamamoto H, Furukawa T.
    Nihon Gan Chiryo Gakkai Shi; 1985 Feb 20; 20(1):25-30. PubMed ID: 3858395
    [No Abstract] [Full Text] [Related]

  • 31. [The contribution of CA 19-9 in the differential diagnosis between chronic pancreatitis and cancer of the pancreas].
    Van Gossum M, Delanghe A, Gerard M, Delcourt A, Deltenre M.
    Acta Gastroenterol Belg; 1987 Feb 20; 50(1):91-4. PubMed ID: 3480672
    [No Abstract] [Full Text] [Related]

  • 32. [Tumor markers in malignancies of the gastrointestinal tract].
    von Kleist S, Hohneck A.
    Internist (Berl); 1982 Jan 20; 23(1):10-2. PubMed ID: 6175599
    [No Abstract] [Full Text] [Related]

  • 33. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R, Billi P, Plate L, Laudadio MA, Sprovieri G.
    Ital J Gastroenterol; 1995 Jan 20; 27(6):296-9. PubMed ID: 8562994
    [Abstract] [Full Text] [Related]

  • 34. Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies.
    Yoshikawa T, Nishida K, Tanigawa M, Fukumoto K, Kondo M.
    Digestion; 1985 Jan 20; 31(2-3):67-76. PubMed ID: 2581838
    [Abstract] [Full Text] [Related]

  • 35. Immunological diagnosis and prognosis of digestive tract cancer: some clinical considerations.
    Zamcheck N.
    Ann Immunol (Paris); 1973 Nov 20; 124(4):635-40. PubMed ID: 4792503
    [No Abstract] [Full Text] [Related]

  • 36. [Antigens associated with cancer of the pancreas].
    Burtin P.
    Bull Cancer; 1990 Nov 20; 77(1):69-73. PubMed ID: 2317577
    [Abstract] [Full Text] [Related]

  • 37. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
    van Dalen A, Kessler AC.
    Eur J Clin Chem Clin Biochem; 1996 Apr 20; 34(4):377-84. PubMed ID: 8704058
    [Abstract] [Full Text] [Related]

  • 38. [CA 19-9 in benign diseases of the gastrointestinal tract].
    Klapdor R.
    Dtsch Med Wochenschr; 1986 Jun 27; 111(26):1039. PubMed ID: 3459644
    [No Abstract] [Full Text] [Related]

  • 39. [Oncofetal antigen].
    Nishida K, Yoshikawa T, Kondo M.
    Nihon Rinsho; 1980 Jun 27; 38(1):152-60. PubMed ID: 6156250
    [No Abstract] [Full Text] [Related]

  • 40. Pancreatic oncofoetal antigen in pancreatic cancer.
    Hobbs JR, Branfoot AC, Knapp ML.
    Practitioner; 1980 Oct 27; 224(1348):1023-7. PubMed ID: 7220429
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.